KR960705062A - PRIMERS AND PROBES FOR THE AMPLIFICATION AND DETECTION OF CMV NUCLEIC ACID - Google Patents

PRIMERS AND PROBES FOR THE AMPLIFICATION AND DETECTION OF CMV NUCLEIC ACID

Info

Publication number
KR960705062A
KR960705062A KR1019960701958A KR19960701958A KR960705062A KR 960705062 A KR960705062 A KR 960705062A KR 1019960701958 A KR1019960701958 A KR 1019960701958A KR 19960701958 A KR19960701958 A KR 19960701958A KR 960705062 A KR960705062 A KR 960705062A
Authority
KR
South Korea
Prior art keywords
sequence
nucleic acid
primer
mrna
acid sequence
Prior art date
Application number
KR1019960701958A
Other languages
Korean (ko)
Other versions
KR100399715B1 (en
Inventor
테오도루스 게라르두스 실레켄스 페터
카타리나 안나 클라지나 팀머만스 에벨린
Original Assignee
에프. 지. 엠. 헤르만스 · 이.에이치. 리이링크
악조 노벨 엔.브이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에프. 지. 엠. 헤르만스 · 이.에이치. 리이링크, 악조 노벨 엔.브이. filed Critical 에프. 지. 엠. 헤르만스 · 이.에이치. 리이링크
Publication of KR960705062A publication Critical patent/KR960705062A/en
Application granted granted Critical
Publication of KR100399715B1 publication Critical patent/KR100399715B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/705—Specific hybridization probes for herpetoviridae, e.g. herpes simplex, varicella zoster
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention relates to a method for the diagnosis of symptomatic CMV disease, characterized in that the presence of mRNA encoding a late structural protein of the human Cytomegalovirus in a blood sample of an individual, suspected of carrying said disease, is detected, said method comprising the following steps: amplifying a target sequence within said mRNA using a primer pair capable of specifically reacting with said target sequence and suitable amplification reagents, reacting the sample, optionally containing amplified nucleic acid, with a labeled nucleic acid probe having a sequence complementary to part of the target sequence, detecting hybrids formed between the target sequence and the probe. The present invention further provides primers and probes for the amplification and detection of late pp67 HCMV mRNA.

Description

CMV 핵산 증폭 및 검출용 프라이머와 프로브(PRIMERS AND PROBES FOR THE AMPLIFICATION AND DETECTION OF CMV NUCLEIC ACID)PRIMERS AND PROBES FOR THE AMPLIFICATION AND DETECTION OF CMV NUCLEIC ACID

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.

Claims (11)

-표적 서열과 특이적으로 반응할 수 있는 프라이머 쌍과 적합한 증폭시약을 사용하여 인체 사이토메갈로바이러스의 후기 구조 단백질을 암호하는 mRNA내에서 상기 표적 서열을 증폭시키는 단계; -임의로 증폭된 핵산을 함유하는, 중후성 CMV 질환을 보유하고 있는 것으로 추정되는 개체의 혈액 샘플을 상기 증폭된 서열의 일부에 상보적인 서열을 가진 표지된 핵산 프로브와 반응시키는 단계; 및-상기 증폭된 서열과 프로브 사이에서 형성된 하이브리드를 검출하는 단계를 포함하며, 중후성 CMV 질환을 보유하고 있는 것으로 추정되는 개체의 혈액 샘플에서 인체 사이토메갈로바이러스의 후기 구조 단백질을 암호하는 mRNA의 존재를 검출하는 것을 특징으로 하는 중후성 CMV 질환 진단 방법.Amplifying said target sequence in mRNA encoding late structural proteins of human cytomegalovirus using primer pairs and suitable amplification reagents that can specifically react with the target sequence; -Reacting a blood sample of an individual suspected of having a profound CMV disease containing amplified nucleic acid with a labeled nucleic acid probe having a sequence complementary to a portion of the amplified sequence; And-detecting the hybrid formed between the amplified sequence and the probe, wherein the presence of mRNA encoding a late structural protein of the human cytomegalovirus in a blood sample of the individual suspected of having a severe CMV disease A method for diagnosing profound CMV disease, characterized in that the detection of. 제1항에 있어서, 상기 mRNA가 pp67 mRNA인 것을 특징으로 하는 방법.The method of claim 1, wherein said mRNA is pp67 mRNA. 제1항 또는 제2항에 있어서, 전사 의거한 증폭 기술을 이용하여 상기 mRNA를 증폭시키는 것을 특징으로 하는 방법.The method of claim 1 or 2, wherein said mRNA is amplified using a transcription-based amplification technique. 제3항에 있어서, 상기 증폭기 기술이 NASBA인 것을 특징으로 하는 방법.4. The method of claim 3, wherein the amplifier technology is NASBA. HCMV pp67을 암호하는 핵산 서열의 일부에 대응하며, 길이가 10~35 뉴클레오티드이고, 5′-GGGTCGATTCGAGACCGA-3′, 5′-GGGTCGATTC-AGACTGA-3′, 5′-GACCTGATATCCCTCCATATA-3′또는 이것의 상보적인 서열로 이루어진 군중에서 선택된 서열중 10개 이상의 뉴클레오티드로된 단편을 포함하는 울리고뉴클레오티드.Corresponds to a portion of the nucleic acid sequence encoding HCMV pp67, is 10-35 nucleotides in length, 5′-GGGTCGATTCGAGACCGA-3 ′, 5′-GGGTCGATTC-AGACTGA-3 ′, 5′-GACCTGATATCCCTCCATATA-3 ′ or its complement Ringing nucleotides comprising fragments of at least 10 nucleotides of the sequence selected from the group consisting of a sequence. 제5항에 있어서, 프로모터 서열에 결합된 울리고뉴클레오티드.6. The ringing nucleotide of claim 5 bound to a promoter sequence. 본질적으로 핵산 서열 5′-aattctaatacgactcactatagggagaGGGTCGATTCAGACTGA-3′로 이루어진 제1프라이머와 본질적으로 핵산 서열 5′-GACCTGATATCCCTCCATATA-3′로 이루어진 제2프라이머를 포함하는, HCMV pp67 서열내에 위치한 표적 서열 증폭용 프라이머 세트.A primer set for amplifying a target sequence located within an HCMV pp67 sequence comprising a first primer consisting essentially of the nucleic acid sequence 5'-aattctaatacgactcactatagggagaGGGTCGATTCAGACTGA-3 'and a second primer consisting essentially of the nucleic acid sequence 5'-GACCTGATATCCCTCCATATA-3'. 본질적으로 핵산 서열 5′-aattctaatacgactcactatagggagaGGGTCGATTCAGACTGA-3′로 이루어진 제1프라이머와 본질적으로 핵산 서열 5′-GACCTGATATCCCTCCATATA-3′로 이루어진 제2프라이머를 포함하는, HCMV pp67 서열내에 위치한 표적 서열 증폭용 프라이머 세트.A primer set for amplifying a target sequence located within an HCMV pp67 sequence comprising a first primer consisting essentially of the nucleic acid sequence 5'-aattctaatacgactcactatagggagaGGGTCGATTCAGACTGA-3 'and a second primer consisting essentially of the nucleic acid sequence 5'-GACCTGATATCCCTCCATATA-3'. 제2항의 방법에 프라이머로서 제5항에 따른 올리고뉴클레오티드를 사용하는 방법.A method according to claim 2, wherein the oligonucleotide according to claim 5 is used as a primer. 제2항의 방법에 프로브로서, 본질적으로 검출가능한 표지가 제공된 서열 5′-GGATTCGGACTTTCCGTTCGA-3′로 이루어진 올리고뉴클레오티드를 사용하는 방법.The method of claim 2, wherein as a probe, an oligonucleotide consisting of the sequence 5′-GGATTCGGACTTTCCGTTCGA-3 ′ provided with a detectable label is provided. -하나 이상의 제7항 및/또는 제8항에 따른 프라이머 세트(들) 및-상기 프라이머 세트에 의해 한정된 증폭 핵산 서열의 최소한 일부에 거의 상보적이고, 검출가능한 표지가 제공된 핵산 서열을 포함하는 올리고뉴클레오티드를 포함하는 HCMV 질환 진단용 시험 키트.An oligonucleotide comprising one or more primer set (s) according to claims 7 and / or 8 and a nucleic acid sequence provided with a detectable label that is substantially complementary to at least a portion of the amplification nucleic acid sequence defined by said primer set. HCMV disease diagnostic test kit comprising a. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019960701958A 1994-08-18 1995-08-18 Primers and Probes for CMV Nucleic Acid Amplification and Detection KR100399715B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP94202360 1994-08-18
EP94202360.7 1994-08-18

Publications (2)

Publication Number Publication Date
KR960705062A true KR960705062A (en) 1996-10-09
KR100399715B1 KR100399715B1 (en) 2003-12-18

Family

ID=8217105

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019960701958A KR100399715B1 (en) 1994-08-18 1995-08-18 Primers and Probes for CMV Nucleic Acid Amplification and Detection

Country Status (12)

Country Link
EP (1) EP0729518B1 (en)
JP (1) JPH09504182A (en)
KR (1) KR100399715B1 (en)
AT (1) ATE209691T1 (en)
AU (1) AU707317B2 (en)
CA (1) CA2172142C (en)
DE (1) DE69524199T2 (en)
DK (1) DK0729518T3 (en)
ES (1) ES2169146T3 (en)
FI (1) FI120912B (en)
PT (1) PT729518E (en)
WO (1) WO1996006191A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA981491B (en) * 1997-02-28 1998-08-20 Akzo Nobel Nv Oligonucleotides that can be used in the amplification and detection of cmv nucleic acid
ZA99362B (en) 1998-01-23 1999-07-19 Akzo Nobel Nv EF-Tu mRNA as a marker for viability of bacteria.
EP1211323A1 (en) * 2000-12-04 2002-06-05 Amsterdam Support Diagnostics B.V. Tests based on nucleic acids of endosymbiont cellular organelles
JP4472253B2 (en) 2000-12-04 2010-06-02 プリマゲン ベー．フェー． Examination of internal symbiotic organelles and compounds identifiable thereby
US9085808B2 (en) 2011-01-12 2015-07-21 Abbott Molecular Inc. Materials and method for detecting cytomegalovirus (CMV)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1340807C (en) * 1988-02-24 1999-11-02 Lawrence T. Malek Nucleic acid amplification process
CA2124796A1 (en) * 1991-12-23 1993-07-08 Chiron Diagnostics Corporation Cmv probes for use in solution phase sandwich hybridization assays
EP0586011A2 (en) * 1992-08-28 1994-03-09 Eastman Kodak Company Methods for production and amplification of nucleic acids

Also Published As

Publication number Publication date
PT729518E (en) 2002-05-31
FI120912B (en) 2010-04-30
FI961678A (en) 1996-04-17
CA2172142A1 (en) 1996-02-29
AU3346995A (en) 1996-03-14
FI961678A0 (en) 1996-04-17
JPH09504182A (en) 1997-04-28
EP0729518B1 (en) 2001-11-28
WO1996006191A2 (en) 1996-02-29
ATE209691T1 (en) 2001-12-15
KR100399715B1 (en) 2003-12-18
CA2172142C (en) 2010-01-12
DE69524199T2 (en) 2002-05-02
AU707317B2 (en) 1999-07-08
EP0729518A1 (en) 1996-09-04
ES2169146T3 (en) 2002-07-01
DE69524199D1 (en) 2002-01-10
DK0729518T3 (en) 2002-03-18
WO1996006191A3 (en) 1996-03-14

Similar Documents

Publication Publication Date Title
CA2143202C (en) Elimination of false negatives in nucleic acid detection
CA2262403A1 (en) Biomarkers and targets for diagnosis, prognosis and management of prostate disease
EP0664339A1 (en) Method of discriminating nucleic acid and testing set for discriminating nucleic acid
EP0892856B1 (en) A method for the amplification and detection of a nucleic acid fragment of interest
JP2939485B2 (en) Amplification / detection system based on replicated RNA
AU1010688A (en) Diagnostic assays using nucleic acid probes
Rola et al. The detection of bovine leukemia virus proviral DNA by PCR–ELISA
WO1997032044A9 (en) A method for the amplification and detection of a nucleic acid fragment of interest
DE60219813D1 (en) TEST STRIP PROBE SYSTEM AND METHOD FOR DETECTING SPECIFIC NUCLEIC ACID SEQUENCES
US5876937A (en) Method for determining the integrity of nucleic acid
WO1995033854B1 (en) Use of a specific marker for detection of salmonella with pcr
KR960705062A (en) PRIMERS AND PROBES FOR THE AMPLIFICATION AND DETECTION OF CMV NUCLEIC ACID
Espy et al. Comparison of SHARP signal system and Southern blot hybridization analysis for detection of cytomegalovirus in clinical specimens by PCR
AU735471B2 (en) Oligonucleotides that can be used in the amplification and detection of CMV nucleic acid
JPH11243995A (en) Detection of urinary bladder cancer in urine sample
WO2000011215A2 (en) Method for diagnostic screening
CN117305521A (en) Kit for detecting herpes simplex virus in sample based on MIRA and application thereof
EP0543222A1 (en) Method for detecting nucleic acids and relative diagnostic kit
CN116042908A (en) Kit for rapidly detecting combination of RPA amplification and flow-measuring chromatographic immunoassay test strip of African swine fever virus
WO1999024607A3 (en) DETECTION AND TYPING OF THE iceA GENE OF $i(HELICOBACTER PYLORI)

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20120822

Year of fee payment: 10

FPAY Annual fee payment

Payment date: 20130909

Year of fee payment: 11

EXPY Expiration of term